Compugen Ltd.. (5/23/17). "Press Release: Compugen to Present at Two Upcoming Investor Conferences in June". Holon.

	Region	New York, NY
	Country	United States (USA)
	Organisation	Compugen Ltd. (Nasdaq: CGEN)
	Group	Compugen (Group)
	Organisation 2	Jefferies Group Inc.
	Today	Jefferies LLC
	Group	Leucadia (Group)
	Product	Jefferies 2017 Global Healthcare Conference New York
	Product 2	JMP Securities Life Sciences Conference 2017 New York
	Index term	Compugen–Leucadia: investor conference, 201706 supply service Compugen presents at Jefferies Healthcare Conference in New York
	Index term 2	Compugen–JMP Securities: investor conference, 201706 supply service Compugen presents at JMP Securities 2017 Life Sciences Conference NY
	Person	Cohen-Dayag, Anat (Compugen 201112 CEO)
	Person 2	Chau, Susanna (Compugen 201702 Director IR + Corp Communiations)

Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer, will present at two investor conferences in New York in June:

• Jefferies Global Healthcare Conference on Tuesday, June 6 at 2:00 pm ET. A live webcast and slide presentation will be available on the Company’s website.

• JMP Securities Life Science Conference on Wednesday, June 21 at 9:00 am ET. The format will be a panel discussion titled, “Immuno-oncology: From the Lab to the Clinic.”

About Compugen

Compugen is a leading therapeutic discovery company whose mission is to utilize its broadly applicable predictive discovery infrastructure to discover novel drug targets and develop first-in-class therapeutics. Our current pipeline consists of early and preclinical stage immuno-oncology programs based on novel drug targets discovered internally, primarily immune checkpoint and myeloid protein target candidates. These programs focus on the development of first-in-class cancer immunotherapy drugs with the potential to harness the immune system to provide treatment solutions in areas of unmet medical need in various cancer types and patient populations, both as monotherapy and in combination with other drugs. In addition, our pipeline currently includes a preclinical fusion protein autoimmune product candidate. Compugen’s business model is based on selectively entering into collaborations for its novel target candidates and related drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, therapeutic monoclonal antibodies are discovered and developed against the Company’s novel drug target candidates. For additional information, please visit Compugen's corporate website at http://www.cgen.com.

Company contact:

Susanna Chau
Director, Investor Relations and Corporate Communications
Compugen
Email: susannac@cgen.com
Tel: +1 (650) 263-7001

Record changed: 2023-06-05